Physician profile
Todd D Edwards
NPI 1639261001
$2,795.65
in general payments reported to CMS, 2019-2025
21 companies · $46.81 in 2025
The $46.81 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $132 · 2021: $220 · 2022: $636 · 2023: $550 · 2024: $486 · 2025: $46.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $760.56 | 2019-2024 | |
| Abbott Laboratories | $597.62 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Actelion Pharmaceuticals US, INC. | $556.31 | 2019-2024 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $148.48 | 2019-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $144.96 | 2019-2024 | Verquvo, Winrevair |
| Sanofi-Aventis U.S. LLC | $89.67 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.65 | 2022-2025 | |
| Medtronic Vascular, INC. | $60.64 | 2019 | |
| Akcea Therapeutics, INC. | $53.61 | 2019-2020 | |
| Baxter Healthcare | $52.13 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.47 | 2019-2023 | Jardiance |
| Pfizer INC. | $41.60 | 2019-2022 | |
| Boston Scientific Corporation | $26.37 | 2024 | |
| Novo Nordisk INC | $23.96 | 2023 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $17.65 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $17.55 | 2023 | |
| La Jolla Pharmaceutical Company | $17.13 | 2024 | Giapreza |
| Amgen INC. | $15.66 | 2025 | Repatha |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| United Therapeutics Corporation | $13.10 | 2019 | |
| Irhythm Technologies, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.